CWP
MRNA icon

Concord Wealth Partners’s Moderna MRNA Stock Holding History

Concord Wealth Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,998
Closed -$138K – 866
2025
Q2 		$138K Buy
4,998
+4,758
+1,983% +$125K 0.02% 240
2025
Q1 		$6.8K Buy
240
+108
+82% +$3.83K ﹤0.01% 545
2024
Q4 		$5.49K Sell
132
-378
-74% -$18.1K ﹤0.01% 591
2024
Q3 		$34.1K Buy
510
+100
+24% +$9.18K 0.01% 390
2024
Q2 		$48.6K Buy
410
+278
+211% +$35.2K 0.01% 312
2024
Q1 		$14.1K Sell
132
-72
-35% -$7.26K ﹤0.01% 537
2023
Q4 		$20.3K Hold
204
– – ﹤0.01% 476
2023
Q3 		$21.1K Hold
204
– – ﹤0.01% 503
2023
Q2 		$24.8K Hold
204
– – 0.01% 472
2023
Q1 		$31.3K Hold
204
– – 0.01% 418
2022
Q4 		$36.6K Buy
+204
New +$33.4K 0.01% 421
2022
Q3 		– Sell
-204
Closed -$29K – 744
2022
Q2 		$29K Hold
204
– – 0.01% 460
2022
Q1 		$35K Sell
204
-98
-32% -$16.5K 0.01% 497
2021
Q4 		$77K Buy
302
+230
+319% +$67.2K 0.02% 353
2021
Q3 		$28K Hold
72
– – 0.01% 315
2021
Q2 		$17K Sell
72
-57
-44% -$10.2K ﹤0.01% 539
2021
Q1 		$17K Buy
129
+57
+79% +$8.26K 0.01% 505
2020
Q4 		$8K Buy
+72
New +$7.28K 0.01% 376

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Concord Wealth Partners's MRNA Position: Q3 2025 in Review

Concord Wealth Partners sold out of Moderna (MRNA) in Q3 2025, closing a stake of 4,998 shares — an estimated $138K sold.

Concord Wealth Partners first reported a position in MRNA in Q4 2020 and held it in 18 quarters. The position peaked at $138K in Q2 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Concord Wealth Partners reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Concord Wealth Partners sold 4,998 Moderna shares in Q3 2025, an estimated $138K.
  • Concord Wealth Partners first reported a position in Moderna in Q4 2020 and held it in 18 quarters.
  • Concord Wealth Partners's Moderna position peaked at $138K in Q2 2025.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Concord Wealth Partners's 13F filing for Q3 2025, filed 5 Nov 2025.